| # | Drug | Count |
|---|---|---|
| 0 | SODIUM CHLORIDE | 324 |
| 1 | SODIUM CHLORIDE TABLET | 323 |
| 2 | SODIUM CHLORIDE TABLETS | 323 |
| 3 | CYCLOPHOSPHAMIDE | 228 |
| 4 | CYCLOPHOSPHAMIDE FOR INJECTION | 228 |
| 5 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 228 |
| 6 | CYTARABINE | 164 |
| 7 | PACLITAXEL | 142 |
| 8 | PACLITAXEL (AIBUMIN-BOUND) | 139 |
| 9 | CARBOPLATIN | 135 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | IDARUBICIN HYDROCHLORIDE | 15 | 0.0129 |
| 1 | EPIRUBICIN HYDROCHLORIDE | 68 | 0.0105 |
| 2 | DAUNORUBICIN HYDROCHLORIDE | 11 | 0.0067 |
| 3 | STERILE WATER FOR INJECTION | 31 | 0.0057 |
| 4 | SODIUM CHLORIDE TABLET | 323 | 0.0043 |
| 5 | SODIUM CHLORIDE TABLETS | 323 | 0.0043 |
| 6 | DEXRAZOXANE FOR INJECTION | 4 | 0.0042 |
| 7 | SODIUM CHLORIDE | 324 | 0.0040 |
| 8 | ZANUBRUTINIB | 18 | 0.0040 |
| 9 | LEVOLEUCOVORIN INJECTION | 12 | 0.0039 |
| # | Drug class | Count |
|---|---|---|
| 0 | Nucleoside Metabolic Inhibitor [EPC] | 381 |
| 1 | Osmotic Laxative [EPC] | 340 |
| 2 | Platinum-based Drug [EPC] | 327 |
| 3 | Alkylating Drug [EPC] | 253 |
| 4 | Microtubule Inhibitor [EPC] | 238 |
| 5 | Corticosteroid [EPC] | 140 |
| 6 | BCL-2 Inhibitor [EPC] | 132 |
| 7 | Kinase Inhibitor [EPC] | 123 |
| 8 | HER2/neu Receptor Antagonist [EPC] | 114 |
| 9 | Epidermal Growth Factor Receptor Antagonist [EPC] | 107 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Endoglycosidase [EPC] | 17 | 0.0092 |
| 1 | CD38-directed Cytolytic Antibody [EPC] | 42 | 0.0072 |
| 2 | Epidermal Growth Factor Receptor Antagonist [EPC] | 107 | 0.0023 |
| 3 | BCL-2 Inhibitor [EPC] | 132 | 0.0021 |
| 4 | Lymphocyte Growth Factor [EPC] | 2 | 0.0016 |
| 5 | HER2/neu Receptor Antagonist [EPC] | 114 | 0.0015 |
| 6 | Bispecific CD20-directed CD3 T Cell Engager [EPC] | 6 | 0.0015 |
| 7 | Microtubule Inhibitor [EPC] | 238 | 0.0014 |
| 8 | Nucleoside Metabolic Inhibitor [EPC] | 381 | 0.0014 |
| 9 | Actinomycin [EPC] | 3 | 0.0014 |